SCHEMBL5784186

SCHEMBL5784186

O=S(=O)(c1ccccc1)c1cn(CCN(Cc2ccccc2)Cc2ccccc2)c2ccccc12

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 19/20 0.71
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5785364 0.82 HTR6 (0.97) HTR6
SCHEMBL5787166 0.79 HTR6 (1.00) HTR6POLB
SCHEMBL5783823 0.79 HTR6 (0.85) HTR6
SCHEMBL5785029 0.76 HTR6 (0.84) HTR6POLB
SCHEMBL3887629 0.76 HTR6 (0.68) HTR6
Hydrochloric Acid SCHEMBL5786408 0.75 HTR6 (0.82) HTR6POLB
SCHEMBL5782859 0.74 HTR6 (0.67) HTR6
SCHEMBL5784898 0.74 HCRTR1 (0.46) HTR6
SCHEMBL27605195 0.73 HTR6 (0.69) HTR6POLB
SCHEMBL5787191 0.72 HTR6 (0.64) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1509501-B1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2006-12-20 EP claimed
US-6727246-B2 ENHANCEMENT OF COGNITION AND MEMORY IN HUMAN DISEASES SUCH AS ALZHEIMER'S WYETH 2004-04-27 US claimed
US-20030232828-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH 2003-12-18 US claimed
EP-1509501-B1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2006-12-20 EP disclosed
EP-1509501-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2005-03-02 EP disclosed
US-6727246-B2 ENHANCEMENT OF COGNITION AND MEMORY IN HUMAN DISEASES SUCH AS ALZHEIMER'S WYETH 2004-04-27 US disclosed
US-20030232828-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH 2003-12-18 US disclosed
WO-2003101962-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232828-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS HTR6, HTR3A, HTR5A HTR6 1/4885POLB 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.